Aug. 31, 2022 –The FDA on Wednesday granted emergency use authorization to Omicron-specific COVID-19 vaccines made by Pfizer/BioNTech and Moderna.
The company cited information to help the security and efficacy of this subsequent era of mRNA vaccines focused towards variants of concern.
If you happen to’ve been ready to get a variant-specific booster shot, it’s possible you’ll be in luck as early as subsequent week.
The Pfizer EUA corresponds to the corporate’s mixture booster shot that features the unique COVID-19 vaccine in addition to a vaccine particular designed to guard in opposition to the newest Omicron variants, BA.4 and BA.5.
The Moderna mixture vaccine will comprise each the agency’s unique COVID-19 vaccine and a vaccine to guard particularly in opposition to Omicron BA.4 and BA.5 subvariants.
As of August 27, BA.4 and BA.4.6 account for about 11% of circulating variants and BA.5 accounts for nearly all of the remaining 89%, CDC information present.
The following step shall be evaluate of the scientific information by the CDC’s Advisory Committee on Immunization Practices, which is about to satisfy Sept. 1 and a pair of. The ultimate hurdle earlier than distribution of the brand new vaccines shall be sign-off on CDC suggestions to be used by company Director Rochelle Walensky, MD.
This can be a growing story. Please verify again for updates.